Oral and inhaled Nadolol are two separate programmes. Smoking...

Oral and inhaled Nadolol are two separate programmes. Smoking cessation is about the only market which will accept an oral drug, given the competition in the market place. I would expect that it will be snapped up by one of the majors with a large market in this space. In fact, I do not see how Pfizer can let it go to anyone else. They are in big trouble with their current drug, having recently settled a class action for about $300M. It is a pretty important market for them. It is also quick to market.
The inhaled programme is a little different. It has to start from scratch, with some animal trials, Phase 1 and so on. It will then have to establish a market. A very much larger investment but huge rewards. I can't see one crowding out the other.